产品描述信息
NR-18683??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 2834 (MT1304, Rv1266c)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 2834 (MT1304, Rv1266c)|2°C to 8°C|NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 2834 (MT1304, Rv1266c), NR-18683."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.In 2002,
TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 2834 was created by disruption of a probable transmembrane serine/threonine-protein kinase (MT1304, Rv1266c), of the wild-type strain CDC1551.Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 4 weeks at 37°C.TARGET:
Rv1266cMT Number (JCVI):
MT1304TubercuList:
Rv1266cORF Description: probable transmembrane serine/threonine-protein kinaseORF Size: 1881POI: 595Additional information is available at
Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed:
12775759.